Best of ASCO 2023 Annual Meeting
  1. Página Inicial

Programação

Filtrar atividades
Plenária
11:45 - 13:00 Módulo

Módulo Gastrointestinal

11:45 - 11:50
Abstract 4008
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
11:50 - 11:55
Abstract 4002
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
11:55 - 12:00
LBA 4005
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
12:00 - 12:07
Abstract 3506
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
12:07 - 12:15
Abstract 3507
Oral session Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
12:15 - 12:20
LBA2
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
12:20 - 12:25
Abstract 3505
Oral session Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
12:25 - 12:30
Abstract 3501
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
12:30 - 13:00
Discussão